What Actually Causes GERD and Acid Reflux? Why Long-Term PPI Use Often Makes It Worse

GERD is not always a disease of "too much stomach acid." It is, in most cases, a disease of the lower esophageal sphincter (LES) failing to close properly, with secondary contributions from pressure pushing upward from below (gastroparesis, SIBO gas production, chronic constipation, abdominal weight, hiatal hernia), from impaired esophageal clearance, and from the mucosal sensitivity of the lower esophagus. Stomach acid is the proximate trigger of the symptom, but the mechanism producing the symptom is mechanical and inflammatory rather than acidotic. This matters because the standard treatment, PPI acid suppression, addresses the proximate trigger without addressing the mechanism. Acid suppression provides real symptomatic relief for many patients. It also produces a cascade of downstream consequences when used long term, including SIBO development, B12 and magnesium depletion, increased risk of certain infections, and rebound acid hypersecretion that makes coming off the medication unusually difficult. Approximately 15 million Americans are on long-term PPI therapy. A substantial fraction of them are worse off, mechanistically, than they were before treatment, even when their symptoms are controlled. Understanding what is actually driving the GERD allows for a more durable approach.

The clinical pattern that defines treatment-resistant GERD

A patient presents with heartburn, regurgitation, and chest discomfort after meals, often worsening when lying down. The symptoms have been present for months or years. A trial of over-the-counter antacids provided partial relief. The primary care physician prescribed a PPI. The reflux symptoms improved substantially. The patient has remained on the PPI for years, often a decade or longer. Over time, the dose has been increased, or a second daily dose was added, or the patient switched between different PPIs trying to find one that worked better.

In the more recent years, new symptoms have appeared. Bloating after meals. Persistent fullness. Food sensitivities to items that were previously tolerated. Constipation or alternating bowel patterns. Fatigue. Brain fog. Occasional palpitations. The patient may have been told they have IBS, or SIBO, or functional dyspepsia, depending on which specialist they saw. The reflux symptoms have either persisted despite the medication or partially returned, prompting consideration of adding a histamine blocker (H2 antagonist) or trying a different PPI.

The patient tries to come off the PPI. The reflux symptoms return within days, often worse than before treatment began. This is interpreted as confirmation that the medication is necessary. The patient resumes the PPI. The cycle continues. Some patients accept the lifelong medication. Others continue searching for an alternative and arrive at functional medicine or integrative care looking for a way out.

This pattern is one of the most common in adult gastroenterology. The clinical literature has begun to acknowledge the limits of long-term PPI use. The American Gastroenterological Association, the American College of Gastroenterology, and the FDA have issued varying degrees of caution about long-term use. The clinical practice has changed slowly. Many patients remain on long-term PPI therapy without a clear reassessment of whether they need it, what the long-term consequences are, and what alternatives exist.

The Host Capacity Model framework offers a different reading of GERD that addresses why the symptoms persist, why long-term PPI use creates new problems, and what a more durable approach looks like.

Why "too much stomach acid" is rarely the actual mechanism

The lay understanding of GERD is that the stomach produces too much acid, the acid backs up into the esophagus, and the acid burns the esophageal lining. Suppressing the acid solves the problem. This narrative is intuitive but mechanistically incorrect for most patients.

The amount of acid the stomach produces is not the primary determinant of whether reflux occurs. Patients with GERD frequently have normal or even reduced gastric acid output (hypochlorhydria) on careful testing. The actual mechanism of reflux involves the lower esophageal sphincter, the muscular valve at the junction between the esophagus and the stomach. When the LES is functioning properly, it remains closed between swallows, allowing the stomach to retain its contents under positive pressure. When the LES fails to close properly, stomach contents (which include acid in normal amounts, but also bile, pepsin, and partially digested food) flow upward into the esophagus, where the mucosa is not designed to handle them.

The LES can fail in several ways. Transient LES relaxations occur when the LES briefly opens at inappropriate times, allowing reflux. These transient relaxations are the most common mechanism of GERD and are triggered by gastric distension, by certain foods (alcohol, caffeine, fat, mint), by certain medications, and by mechanical pressure on the stomach. Persistent LES hypotonia (a chronically weak LES) is less common but occurs in some patients, often associated with hiatal hernia or with connective tissue disorders. Anatomical disruption of the diaphragmatic component of the LES, in hiatal hernia, removes one of the mechanical supports of the sphincter and allows reflux to occur more easily.

Notice what is not in this list. The amount of acid is not in this list. The acid the stomach produces is the same with or without an LES that is closing properly. The acid is what produces the symptom when reflux occurs, but the failure of the LES is what allows the reflux to occur in the first place.

This is why PPI suppression of acid production provides symptomatic relief without addressing the mechanism. The acid is suppressed. When reflux still occurs (because the LES is still failing), the refluxate is less acidic and produces less burning. The symptoms improve. The underlying LES dysfunction continues. The reflux continues, in many cases, with less perceived symptom intensity.

What actually drives the LES dysfunction

Five mechanisms contribute to LES dysfunction in GERD. Most patients have features of several.

Mechanism 1: Pressure from below

The LES is positioned at the junction between two pressure systems. The thoracic cavity above is at negative pressure relative to atmospheric. The abdominal cavity below is at positive pressure. The LES holds the gastric contents in the higher-pressure stomach against the lower-pressure esophagus.

When pressure in the abdominal cavity rises, the LES has more work to do. Several conditions raise intra-abdominal pressure substantially. Obesity, particularly central adiposity, increases baseline abdominal pressure throughout the day. Pregnancy raises pressure mechanically and through progesterone-mediated LES relaxation. Chronic constipation produces colonic distension that displaces other organs and raises pressure. Gastroparesis produces gastric distension that directly pushes against the LES. Most relevantly for the framework: SIBO produces substantial fermentation gas that distends the small intestine and stomach, pushing upward against the LES from below.

This is the connection between SIBO and GERD that the standard treatment paradigm misses. The PPI suppresses the acid that produces the burning symptom, but the SIBO continues to produce gas, the gas continues to distend the upper GI tract, and the pressure continues to push reflux through the LES. Many GERD patients have undiagnosed SIBO. Treating the SIBO (per the recurrent SIBO framework) often produces substantial improvement in reflux symptoms because it reduces the pressure pushing from below.

The vicious cycle that PPI use can create operates through this mechanism. PPIs suppress gastric acid, which reduces the bacterial defense provided by the acidic gastric environment. Bacteria that would have been killed by gastric acid survive and can colonize the small intestine, contributing to SIBO development. The SIBO produces gas. The gas increases pressure. The pressure increases reflux. The patient needs more PPI to suppress the symptom. The increased PPI further suppresses acid, further reducing bacterial defense, further supporting SIBO. The cycle perpetuates the underlying disease while suppressing its symptom. The patient becomes more PPI-dependent over time even as the underlying pathophysiology worsens.

Mechanism 2: Mechanical LES disruption

Hiatal hernia is the most common mechanical disruption of the LES. The diaphragm normally provides an external support to the LES through the crural fibers that surround it. In hiatal hernia, the gastroesophageal junction migrates upward through the diaphragm, separating the LES from its diaphragmatic support. The LES loses one of its mechanical defenses.

Small hiatal hernias are common and often asymptomatic. Larger hiatal hernias, or paraesophageal hernias, can be major drivers of refractory GERD. The treatment of significant hiatal hernia is surgical (Nissen fundoplication or related procedures), and is appropriately discussed with a gastroenterology surgeon for patients with refractory disease.

Even without hiatal hernia, the integrity of the diaphragmatic component of the LES can be affected by posture, breathing patterns, and core muscle function. Patients who hold their breath, breathe primarily through the chest rather than the diaphragm, or have weak abdominal core muscles often have suboptimal LES support. Diaphragmatic breathing training and core strengthening can produce meaningful improvements in some patients.

Mechanism 3: LES bioenergetic compromise

The LES is muscle. Muscle requires ATP. The energy demands of maintaining tonic contraction (which the LES does between swallows) and of relaxing on command (which it does during swallowing) are substantial. When the muscle's bioenergetic state is compromised, both the tonic contraction and the timing of relaxation become impaired.

This mechanism connects GERD to the broader Host Capacity Model framework. The same bioenergetic compromise described in the recurrent SIBO article, the CD38-NAD+-SIRT3 cascade article, and the fibromyalgia framework operates in smooth muscle including the LES. Patients with chronic inflammatory conditions, with mitochondrial dysfunction, with the CD38-NAD+ depletion characteristic of post-viral or chronic inflammatory states, frequently develop GERD as one expression of their broader bioenergetic compromise.

The clinical signature is GERD that emerges in the context of broader chronic illness, that worsens during inflammatory or post-viral periods, and that improves when the broader bioenergetic state is supported. Magnesium supplementation, which is essential for both ATP synthesis and for smooth muscle function, often produces meaningful improvement in LES tone in these patients.

Mechanism 4: Vagal dysfunction

The LES is innervated by the vagus nerve. Vagal afferent and efferent fibers regulate both the timing and the strength of LES contraction. When vagal function is compromised, the LES regulation becomes erratic. Transient LES relaxations occur more frequently. The coordination between swallowing and LES relaxation is impaired.

Vagal dysfunction in GERD is mechanistically linked to vagal dysfunction in the conditions described in the POTS article and the MCAS four-patterns article. Patients with POTS-spectrum symptoms, with autonomic dysfunction, with the broader vagal compromise that follows post-viral illness or chronic stress, frequently develop GERD as one expression of their autonomic compromise.

The therapeutic implication is that vagal tone restoration (slow-paced breath work, cold-water exposure within tolerance, vagal nerve stimulation devices) can produce meaningful improvement in LES function. This is one of the most underutilized interventions in GERD treatment.

Mechanism 5: Esophageal mucosal sensitivity

Even when the same amount of reflux occurs, different patients experience different symptom severity. The esophageal mucosa varies in its sensitivity. Patients with chronic mucosal inflammation, with mast cell infiltration of the esophageal mucosa (eosinophilic esophagitis being the extreme example), or with the systemic mucosal sensitivity characteristic of MCAS, experience the same amount of acid exposure as more painful and more disruptive.

This explains the heterogeneity in symptom severity that the acid-amount model does not explain. Two patients can have the same amount of reflux on objective pH monitoring. One has severe symptoms. The other has minimal symptoms. The difference is mucosal sensitivity, often related to the broader inflammatory and mast cell biology described in the MCAS framework.

What long-term PPI use actually does

PPIs work by irreversibly inhibiting the H+/K+ ATPase pump in gastric parietal cells, the final step in gastric acid secretion. The inhibition is profound. PPI use typically reduces gastric acid output by 80-95%. The resulting hypochlorhydria has significant downstream consequences.

Consequence 1: SIBO development

Gastric acid is the principal bacterial defense of the upper GI tract. The acidic gastric environment (pH 1.5-3.5 in the unmedicated stomach) kills most bacteria that arrive with food or saliva. When PPI use raises gastric pH above 4-5, this defense is substantially compromised. Bacteria that would have been killed survive and can colonize the small intestine, contributing to SIBO development.

Multiple studies have documented elevated SIBO prevalence in patients on long-term PPI therapy. Meta-analyses suggest the prevalence is approximately 2-3 fold higher in PPI users compared to controls. The mechanism is direct and well-established.

The clinical irony is that the PPI prescribed to treat reflux symptoms can contribute to the development of SIBO, which then produces more reflux through the mechanism described in Mechanism 1. The patient gets sicker over time while symptomatically managed. This is one of the most important reasons to address GERD mechanistically rather than only suppressively.

Consequence 2: Nutrient malabsorption

Gastric acid is required for the absorption of several nutrients. B12 absorption depends on gastric acid for releasing B12 from food proteins and for activating intrinsic factor binding. Long-term PPI use is associated with B12 deficiency, particularly in older patients and in patients with marginal baseline B12 status. Magnesium absorption is similarly affected, and the FDA issued a specific warning about PPI-associated hypomagnesemia in 2011. Iron absorption is reduced because non-heme iron requires gastric acid for solubilization. Calcium absorption is partially impaired, contributing to the fracture risk that has been documented in long-term PPI users.

The nutritional consequences contribute to the "normal labs but feeling terrible" pattern described in the dedicated article. Many patients on long-term PPI therapy have marginal but not frankly deficient nutrient status that does not show up clearly on standard labs but produces real symptoms.

Consequence 3: Increased infection risk

The acidic gastric environment is part of the body's defense against ingested pathogens. PPI-induced hypochlorhydria increases susceptibility to several infections. Clostridium difficile is the most clinically significant; multiple studies have documented increased C. difficile rates in PPI users. Bacterial gastroenteritis from Salmonella, Campylobacter, and certain E. coli strains is also more common. Community-acquired pneumonia rates are modestly elevated in PPI users, likely through aspiration of bacterial colonized refluxate.

Consequence 4: Rebound acid hypersecretion

This is one of the most important and least discussed consequences of long-term PPI use. When acid suppression is maintained for an extended period (weeks to months), the parietal cells respond by upregulating expression of the H+/K+ ATPase and by increasing histamine-induced acid secretion through ECL cell hyperplasia. The net result is that the stomach is primed to produce more acid than baseline when the PPI is stopped.

When the patient discontinues the PPI, the upregulated acid-producing machinery is unmasked. Acid output briefly rises above pre-treatment levels, often dramatically. The patient experiences a flare of reflux symptoms that is worse than what they had before starting the medication. The standard interpretation is that the medication was necessary all along. The actual mechanism is that the medication has produced a temporary hypersecretory state that takes weeks to months to resolve.

The Reimer and colleagues study in 2009 documented this rebound effect in healthy volunteers given PPI for 8 weeks then stopped. Significant fractions of the previously asymptomatic volunteers developed new-onset reflux symptoms after stopping the PPI. The rebound effect resolves over time as the upregulation reverses, but the time course is weeks to months, which is long enough that many patients give up and resume the medication.

The clinical implication is that coming off PPIs requires a structured tapering approach with substitution support during the rebound period. Abrupt discontinuation reliably produces rebound symptoms that the patient interprets as proof of needing the medication. Structured tapering avoids most of this.

Consequence 5: Potential cognitive risks

The PPI-dementia association is one of the most discussed and most controversial of the proposed long-term effects. The Lazarus 2016 cohort study suggested an association between PPI use and incident dementia in older adults, with effect sizes that were modest but statistically significant. Subsequent meta-analyses have produced mixed results, with some confirming the association and others not.

The proposed mechanisms include B12 deficiency contributing to neurological dysfunction (well-established), magnesium deficiency affecting cognition (well-established), altered gut microbiome affecting the gut-brain axis (the framework described throughout this site), and direct effects of PPI on amyloid metabolism in neurons (suggested by some studies, not confirmed).

The causal relationship between PPI use and dementia remains controversial. The plausibility of contributing mechanisms is high. The risk-benefit calculation for long-term PPI use, particularly in older patients with cognitive vulnerability, has shifted in the past decade in the direction of recommending the lowest effective dose for the shortest necessary duration.

What the framework approach to GERD looks like

A treatment approach that addresses the upstream mechanisms of GERD looks different from standard care. The PPI may continue where it is clearly necessary, but at the lowest effective dose, and with simultaneous work on the underlying mechanisms.

The sequence:

First, identify what is driving the LES dysfunction in the specific patient. Is there SIBO contributing to pressure from below? Is there gastroparesis? Is there hiatal hernia? Is there bioenergetic compromise from chronic illness? Is there vagal dysfunction? Most patients have multiple contributors; one or two are usually dominant.

Second, address the pressure-from-below contributors. If SIBO is present, treat per the recurrent SIBO framework. If gastroparesis is contributing, address motility (often through addressing the same vagal and bioenergetic factors). If chronic constipation is contributing, address it with attention to magnesium, hydration, fiber from appropriate sources, and the broader gut framework. Weight optimization if relevant.

Third, support LES function directly. Magnesium glycinate (300-600 mg daily) for smooth muscle function and bioenergetic support. Address any zinc, B-vitamin, or other cofactor deficiencies. Slow-paced diaphragmatic breathing for vagal tone and for the diaphragmatic component of LES support. Postural and lifestyle interventions (head of bed elevation, meal timing 3+ hours before lying down, avoiding LES-relaxing foods at problem meals).

Fourth, address the mucosal layer. DGL (deglycyrrhizinated licorice) before meals supports mucosal integrity and has reasonable evidence in functional dyspepsia. Mastic gum has antimicrobial activity against H. pylori and supports gastric mucosal healing. Melatonin at low doses (3-6 mg at bedtime) has been studied for GERD and may help LES tone and mucosal healing through several mechanisms.

Fifth, address concurrent factors. If MCAS is contributing to esophageal mucosal sensitivity, address per the four-pattern MCAS framework. If autonomic dysfunction is contributing to vagal compromise, address per the POTS framework. If the broader CD38-NAD+-SIRT3 cascade is operating, address it as in other chronic inflammatory states.

Sixth, structured PPI taper for patients on long-term PPI who want to come off. The approach involves: confirming the upstream mechanisms are being addressed first, slowly stepping down the PPI dose over weeks to months (not days), substituting H2 antagonists (famotidine) during the taper to soften the rebound, and using DGL, melatonin, and other support during the rebound period. The taper is conducted in coordination with the prescribing clinician. Some patients can come off completely. Some need to remain on a low maintenance dose. Both are reasonable outcomes when the upstream work is addressed.

The full sequence operates on the timescale of three to nine months for substantial mechanistic improvement. Some patients experience earlier symptom improvement (particularly with the SIBO treatment and magnesium support). The PPI taper itself often takes 8-16 weeks to complete safely.

This is the approach a Biomelogic consultation works through

The deliverable is a written mechanistic analysis that places the GERD case in HCM terms, identifies the dominant drivers in the specific patient, and recommends sequencing for the patient's existing clinical team to implement alongside the conventional gastroenterology management. Biomelogic does not prescribe, does not modify PPI dosing, and does not replace the gastroenterologist managing the case. The work is educational systems-biology analysis delivered in coordination with the medical team. PPI management decisions belong with the prescribing clinician.

Frequently asked questions about GERD and PPI use

Is GERD really caused by too much stomach acid?

In most cases, no. GERD is caused by lower esophageal sphincter dysfunction allowing stomach contents to flow back into the esophagus. The acid is what produces the burning sensation when reflux occurs, but the amount of acid is rarely the primary issue. Many GERD patients have normal or even reduced gastric acid output on careful testing. The LES is the actual lesion.

Why does my PPI not work as well as it used to?

The most common reasons are: tolerance development at the parietal cell level (less common than people think); progression of the underlying LES dysfunction (continuing while the symptom is suppressed); development of SIBO secondary to the PPI use (creating pressure from below that the PPI cannot address); and weight gain or other lifestyle factors that increase the mechanical pressure. The medication is doing what it was designed to do; the underlying disease is progressing through mechanisms the medication does not address.

Are PPIs safe long-term?

The risk-benefit assessment has evolved. PPIs are appropriate for short-term use (weeks to months) for active reflux disease. Long-term use (years) is associated with increased risk of SIBO, B12 deficiency, magnesium depletion, fractures, C. difficile infection, pneumonia, and possibly cognitive decline. None of these risks are dramatic individually, but they accumulate over years. For patients with clear indications (Barrett's esophagus, severe erosive esophagitis, certain other specific conditions), the benefits may outweigh the risks. For patients on PPIs for non-erosive reflux or for vague upper GI symptoms, the risk-benefit increasingly favors finding alternatives.

Can I just stop taking my PPI?

Stopping abruptly almost always produces rebound acid hypersecretion with worse reflux symptoms than the patient had before starting treatment. This is the rebound effect documented by Reimer et al. and others. It is not evidence that the medication was necessary; it is a temporary consequence of having taken the medication. A structured taper over 8-16 weeks, with substitution support during the rebound period, is the appropriate approach. This should be coordinated with the prescribing clinician.

What should I take instead of my PPI?

That depends on what is driving your reflux. There is no universal answer. For patients with SIBO-driven reflux, treating the SIBO is the priority. For patients with LES bioenergetic compromise, magnesium and the broader cofactor work helps. For patients with mucosal sensitivity, DGL, melatonin, and mucosal support work. For patients with significant hiatal hernia, surgical evaluation may be appropriate. The framework identifies which intervention applies to which patient.

What about famotidine (Pepcid) as an alternative?

Famotidine is an H2 antagonist that reduces acid production through a different mechanism than PPIs. It produces less complete acid suppression than PPIs (typically 50-70% reduction vs 80-95%), which means it preserves more of the bacterial defense of the gastric environment while still providing meaningful symptom relief. Famotidine is often a reasonable bridge during a PPI taper and is sometimes used as a maintenance medication for patients who need ongoing acid suppression but want to reduce PPI exposure.

What about apple cider vinegar for reflux?

Apple cider vinegar is sometimes recommended for reflux on the theory that low stomach acid (rather than high stomach acid) is the cause. The theory is overstated, but there is a kernel of truth: some patients with reflux have hypochlorhydria, and these patients sometimes do respond to acid support rather than acid suppression. The clinical pattern of hypochlorhydric reflux includes bloating, fullness after small meals, difficulty digesting protein, and reflux that worsens rather than improves with food. For these patients, betaine HCl with meals (under appropriate supervision) sometimes produces meaningful improvement. The decision is patient-specific and benefits from clinical guidance.

Is the Host Capacity Model recognized by gastroenterology?

Not in this specific form. The individual mechanisms (PPI-SIBO connection, rebound acid hypersecretion, the mechanical and bioenergetic LES factors) are recognized in the primary research literature. The integration into a clinical framework operating alongside conventional GERD care is novel work being developed through case experience.

Is Mohammed Attallah a doctor?

No. Mohammed Attallah is an independent systems-biology researcher and developer of the Host Capacity Model. He is not a licensed clinician. Biomelogic provides educational systems-biology analysis that operates alongside the client's existing licensed medical team, particularly the gastroenterologist managing any reflux disease. GERD requires ongoing clinical care, and PPI tapering specifically requires the prescribing clinician's involvement.

What does a Biomelogic consultation cost?

The Standard Consultation is $650 one time, which includes the case review, the live session, and the written mechanistic analysis. The full service menu is at biomelogic.net/services. HSA and FSA eligibility varies.

How do I get started?

The lowest-friction starting point is the free 15-minute discovery call. The call determines whether the case is a fit. If yes, the next step is the Standard Consultation.

Working with Biomelogic on GERD and PPI dependency

If the patterns described above resonate with the reflux case you have been navigating, a Biomelogic consultation may be useful. The work is appropriate for patients with an established gastroenterology relationship, who are interested in understanding the mechanistic layer that conventional GERD care does not address, who want to explore alternatives to long-term PPI dependence, or who have tried unsuccessfully to come off PPIs in the past.

The lowest-friction starting point is the free 15-minute discovery call.

For patients ready to proceed directly to a full case workup, the Gate 1 intake form is the starting point.

For gastroenterologists and integrative practitioners working with PPI-dependent patients or with treatment-resistant GERD, the Practitioner Collaboration service provides a mechanistic re-read of a single case with the practitioner present.

For readers wanting the deeper framework, The Host Capacity Model is the canonical framework page.

Related articles

Why does SIBO keep coming back after treatment? — the gut bioenergetic mechanism that PPI use often contributes to

Why doesn't MCAS respond to standard treatment? — the mast cell mechanism that drives esophageal mucosal sensitivity

What actually causes POTS? — the autonomic mechanism that contributes to vagal LES regulation

The CD38-NAD+-SIRT3 cascade in chronic illness — the regulatory cascade affecting smooth muscle bioenergetics

Why am I so tired when my blood work is normal? — the bioenergetic compromise behind PPI-associated symptoms

The Host Capacity Model: an introduction — the canonical framework

Selected primary research

The mechanisms described in this article are drawn from primary research published over the past two decades. Key references include:

Reimer C, Søndergaard B, Hilsted L, Bytzer P. Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology. 2009;137(1):80-87.

Yadlapati R, Kahrilas PJ. The "dangers" of chronic proton pump inhibitor use. J Allergy Clin Immunol. 2018;141(1):79-81.

Lazarus B, Chen Y, Wilson FP, et al. Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Intern Med. 2016;176(2):238-246.

Compare D, Pica L, Rocco A, et al. Effects of long-term PPI treatment on producing bowel symptoms and SIBO. Eur J Clin Invest. 2011;41(4):380-386.

Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol. 2013;11(5):483-490.

Fossmark R, Martinsen TC, Waldum HL. Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility. Int J Mol Sci. 2019;20(20):5203.

Brusselaers N, Wahlin K, Engstrand L, Lagergren J. Maintenance therapy with proton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open. 2017;7(10):e017739.

Sigterman KE, van Pinxteren B, Bonis PA, et al. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;5:CD002095.

Theisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg. 2000;4(1):50-54.

Pereira SP, Gainsborough N, Dowling RH. Drug-induced hypochlorhydria causes high duodenal bacterial counts in the elderly. Aliment Pharmacol Ther. 1998;12(1):99-104.

These references are starting points. The PPI long-term effects literature, the PPI-SIBO connection literature, and the GERD mechanism literature have each expanded substantially in the past decade.

Mohammed Attallah is an independent systems-biology researcher and founder of Biomelogic, where he develops and applies the Host Capacity Model to complex chronic illness cases. He is not a licensed clinician. The framework is educational systems-biology analysis delivered alongside the client's licensed medical team. GERD requires ongoing specialist care; the framework operates alongside that care, not as a replacement. PPI tapering decisions belong with the prescribing clinician.

Biomelogic is based in Bowie, Maryland and serves clients worldwide via remote consultation.